180 related articles for article (PubMed ID: 29718378)
1. Evaluation of Total and IgA-Specific Antibody Targeting Epstein-Barr Virus Glycoprotein 350 and Nasopharyngeal Carcinoma Risk.
Coghill AE; Bu W; Hsu WL; Nguyen H; Yu KJ; Chien YC; Chen CJ; Cohen JI; Hildesheim A
J Infect Dis; 2018 Aug; 218(6):886-891. PubMed ID: 29718378
[TBL] [Abstract][Full Text] [Related]
2. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
3. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
[TBL] [Abstract][Full Text] [Related]
4. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
[TBL] [Abstract][Full Text] [Related]
6. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
[TBL] [Abstract][Full Text] [Related]
8. Associations between environmental factors and serological Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma in South China.
Zhou T; Yang DW; He YQ; Xue WQ; Liao Y; Zheng MQ; Jia YJ; Yuan LL; Zhang WL; Zeng YX; Jia WH
Cancer Med; 2019 Aug; 8(10):4852-4866. PubMed ID: 31241250
[TBL] [Abstract][Full Text] [Related]
9. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
Coghill AE; Pfeiffer RM; Proietti C; Hsu WL; Chien YC; Lekieffre L; Krause L; Teng A; Pablo J; Yu KJ; Lou PJ; Wang CP; Liu Z; Chen CJ; Middeldorp J; Mulvenna J; Bethony J; Hildesheim A; Doolan DL
Clin Cancer Res; 2018 Mar; 24(6):1305-1314. PubMed ID: 29301829
[No Abstract] [Full Text] [Related]
11. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan.
Pickard A; Chen CJ; Diehl SR; Liu MY; Cheng YJ; Hsu WL; Sun B; Hsu MM; Chen IH; Chen JY; Yang CS; Mittl BL; Chou SP; Ruggles DD; Goldstein AM; Hildesheim A
Int J Cancer; 2004 Aug; 111(1):117-23. PubMed ID: 15185352
[TBL] [Abstract][Full Text] [Related]
15. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Xia C; Zhu K; Zheng G
Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
[TBL] [Abstract][Full Text] [Related]
16. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.
Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646
[TBL] [Abstract][Full Text] [Related]
18. Elevated Epstein-Barr virus seroreactivity among unaffected members of families with nasopharyngeal carcinoma.
Qin HD; Jia WH; Zhang LL; Liu N; Zhou XX; Wang MH; Feng QS; Chen LZ; Zhang Y; Jorgensen TJ; Zeng YX; Shugart YY
J Med Virol; 2011 Oct; 83(10):1792-8. PubMed ID: 21837797
[TBL] [Abstract][Full Text] [Related]
19. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
Xu FH; Xiong D; Xu YF; Cao SM; Xue WQ; Qin HD; Liu WS; Cao JY; Zhang Y; Feng QS; Chen LZ; Li MZ; Liu ZW; Liu Q; Hong MH; Shugart YY; Zeng YX; Zeng MS; Jia WH
J Natl Cancer Inst; 2012 Sep; 104(18):1396-410. PubMed ID: 22972969
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
